1. Clinical spectrum of γδ+ T cell LGL leukemia: Analysis of 20 cases
- Author
-
Pearlie K. Epling-Burnette, Renato Zambello, Laurence Amiot, Thierry Lamy, Thierry Fest, Thomas P. Loughran, Jean Donadieu, G. Semenzato, and A. S. Bourgault-Rouxel
- Subjects
Cancer Research ,biology ,T cell ,CD3 ,hemic and immune systems ,chemical and pharmacologic phenomena ,Hematology ,Gene rearrangement ,CD16 ,medicine.disease ,3. Good health ,stomatognathic diseases ,03 medical and health sciences ,Leukemia ,0302 clinical medicine ,Immunophenotyping ,medicine.anatomical_structure ,Oncology ,Antigen ,030220 oncology & carcinogenesis ,Immunology ,medicine ,biology.protein ,CD8 ,030215 immunology - Abstract
We report on the clinico-biological characteristics of 20 cases of gammadelta T cell large granular lymphocyte (LGL) leukemia. All the data were compared to that of 196 cases with alphabeta T cell subtype, which represents the majority of T cell LGL leukemias. Clinical findings were quite similar in the two groups regarding age, sex ratio, recurrent infections, and association with auto-immune diseases especially rheumatoid arthritis. Gammadelta LGL predominantly expressed a CD3+/CD4-/CD8+/CD16+/CD57+ phenotype, in 50% of cases. Clinical outcome was favorable for these patients with overall survival of 85% at 3 years. Fifty percent of gammadelta patients required treatment and the response to therapy was estimated at 55%. gammadelta and alphabeta T cell LGL leukemia harbor a very similar clinico-biological behavior and represent part of an antigen-driven T cell lymphoproliferation.
- Published
- 2008
- Full Text
- View/download PDF